Fig. 3From: A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinomaSurvival relative to WISP miR-200-signature. DFS in the whole cohort (A) and in the cohort divided quartiles (B). OS in the whole cohort (C). Survival in stage IB tumors (D) and in EGFR mutated tumors (E), DFS and OSBack to article page